Amgen (AMGN) News Today

Amgen Inc. (NASDAQ: AMGN) is under pressure as investors reassess the company’s cardiovascular pipeline after disappointing results from rival Novartis, although encouraging oncology data provide a significant positive counterpoint.

• Positive Sentiment: Amgen reported that its Phase 3 DeLLphi-305 trial met its primary endpoint: Imdelltra, combined with AstraZeneca’s Imfinzi, produced a statistically significant and clinically meaningful overall-survival improvement in first-line extensive-stage small-cell lung cancer versus Imfinzi alone. The study also met progression-free survival and response-rate endpoints, strengthening the commercial outlook for Imdelltra. Amgen Imdelltra Phase 3 results
• Positive Sentiment: William Blair analyst Matt Phipps maintained a Buy rating, citing the Phase 3 Imdelltra results as support for Amgen’s growth prospects. William Blair Buy rating on Amgen
• Neutral Sentiment: Cantor Fitzgerald reaffirmed its Neutral rating and set a $400 price target, indicating limited near-term upside based on its current valuation assessment.
• Neutral Sentiment: Zacks continues to highlight Amgen as a potential long-term growth stock, but the commentary is based primarily on quantitative stock-selection factors rather than a new company-specific catalyst. Zacks long-term growth analysis
• Negative Sentiment: Novartis’ Phase 3 pelacarsen trial reduced Lp(a) cholesterol but failed to reduce cardiovascular events. The result raised doubts about the broader therapeutic approach and increased perceived risk for Amgen’s experimental olpasiran, a key 7,297-patient cardiovascular program. Novartis cholesterol trial setback
• Negative Sentiment: BMO downgraded Amgen to Market Perform from Outperform, citing limited near-term upside and a more balanced risk-reward profile. Broad market weakness tied to higher oil prices and inflation concerns added to the selling pressure. BMO downgrade of Amgen